The P53-MDM2 Interaction in a Cancer-Prone Family, and the Identification of a Novel Therapeutic Target

References

• Hollstein M., Sidransky D., Vogelstein B., Harris C. p53 mutations in human cancer. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Lane D. P. p53 and human cancers. Br Med Bull 1994; 50: 582–99
   PubMed Web of Science ®Google Scholar
• Pietenpol JA, Tokino T., Thiagalingam S., El-Deiry W., Kinzler K. W., Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994; 91: 1998–2002
   PubMed Web of Science ®Google Scholar
• Cho Y., Gorina S., Jeffrey P. D., Pavletich N. P. Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 1994; 265: 346–55
   PubMed Web of Science ®Google Scholar
• Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–45
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. Embo J 1993; 12: 461–8
   PubMed Web of Science ®Google Scholar
• Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857–60
   PubMed Web of Science ®Google Scholar
• Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80–3
   PubMed Web of Science ®Google Scholar
• Ladanyi M., Cha C., Lewis R., Jhanwar S. C., Huvos A. G., Healey J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16–8
   PubMed Web of Science ®Google Scholar
• Leach F. S., Tokino T., Meltzer P., et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231–4
   PubMed Web of Science ®Google Scholar
• Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736–9
   PubMed Web of Science ®Google Scholar
• Cordon C. C., Latres E., Drobnjak M., et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794–9
   PubMedGoogle Scholar
• Otto A., Deppert W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 1993; 8: 2591–603
   PubMedGoogle Scholar
• Landers J. E., Haines D. S., Strauss J3, George D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9: 2745–50
   PubMed Web of Science ®Google Scholar
• Finlay C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13: 301–6
   PubMed Web of Science ®Google Scholar
• Barnes D. M., Hanby A. M., Gillett C. E., et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259–63
   PubMed Web of Science ®Google Scholar
• Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–4
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino T., Velculescu V. E., et al. WAF-1 a potential mediator of p53 tumour suppression. Cell 1994; 75: 817–25
   Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 1994; 75: 805–16
   Google Scholar
• Noda A., Ning Y., Venable S. F., Piera-Smith O. M., Smith J. R. Cloning of a senescent cell-derived inhibitor of DNA sythesis using an expression screen. Exper. Cell. Res 1994; 211: 90–98
   PubMed Web of Science ®Google Scholar
• Midgley C. A., Fisher C. J., Bartek J., Vojtesek B., Lane D., Barnes D. M. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101: 183–9
   PubMed Web of Science ®Google Scholar
• Vojtesek B., Bartek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237–44
   PubMed Web of Science ®Google Scholar
• Picksley S. M., Vojtesek B., Sparks A., Lane D. P. Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523–9
   PubMed Web of Science ®Google Scholar
• Camplejohn R. S., Perry P., Hodgson S. V., et al. A possible screening test for inherited p53-related defects based on the apoptotic responsee of peripheral blood lymphocytes to DNA damage. 1995; 72: 654–662
   Google Scholar
• Donehower L. A., Harvey M., Slagle B. L., et al. Mice deficient for p53 are developmental normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–21
   PubMed Web of Science ®Google Scholar
• Birch J. M., Heighway J., Teare M. D., et al. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 1994; 70: 1176–81
   PubMedGoogle Scholar
• Forus A., Florenes V. A., Maelandsmo G. M., et al. Mapping of amplification units in the q13–14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 1993; 4: 1065–70
   PubMedGoogle Scholar
• Florenes V. A., Maelandsmo G. M., Forus A., Andreassen A., Myklebost O., Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297–302
   PubMed Web of Science ®Google Scholar
• Chen J., Marechal V., Levine A. J. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107–14
   PubMed Web of Science ®Google Scholar
• Marston N. J., Crook T., Vousden K. H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 1994; 9: 2707–16
   PubMedGoogle Scholar
• Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional actviation binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8: 1235–46
   PubMed Web of Science ®Google Scholar
• Thut C. J., Chen J-L, Klemm R., Tijan R. p53 transcriptional activation mediated by coactivators TAF1140 and TAF1160. Science 1995; 267: 100–3
   PubMedGoogle Scholar
• Legros Y., Lafon C., Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 1994; 9: 2071–6
   PubMedGoogle Scholar
• Stephen C. W., Helmenin P., Lane D. P. characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 1995; 248: 58–78
   PubMedGoogle Scholar
• Lane DP. Cancer p53 guardian of the genome. Nature 1992; 358: 15–6
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Jacks T., Housman D. E., Ruley H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994; 91: 2026–30
   PubMed Web of Science ®Google Scholar